The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibacterial (Drug) Resistance Market Research Report 2025
Synopsis
Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. Resistance can arise through mutations or can be acquired from other bacteria through plasmids.
The global Antibacterial (Drug) Resistance market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibacterial (Drug) Resistance, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibacterial (Drug) Resistance.
Report Scope
The Antibacterial (Drug) Resistance market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibacterial (Drug) Resistance market comprehensively. Regional market sizes, concerning products by Type, by Indication, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibacterial (Drug) Resistance manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Indication, and by regions.
Market Segmentation
By Company
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
Segment by Type
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS
Segment by Indication
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Indication, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antibacterial (Drug) Resistance in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. Resistance can arise through mutations or can be acquired from other bacteria through plasmids.
The global Antibacterial (Drug) Resistance market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibacterial (Drug) Resistance, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibacterial (Drug) Resistance.
Report Scope
The Antibacterial (Drug) Resistance market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibacterial (Drug) Resistance market comprehensively. Regional market sizes, concerning products by Type, by Indication, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibacterial (Drug) Resistance manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Indication, and by regions.
Market Segmentation
By Company
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
Segment by Type
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS
Segment by Indication
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Indication, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antibacterial (Drug) Resistance in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Antibacterial (Drug) Resistance Market Overview
1.1 Product Overview and Scope of Antibacterial (Drug) Resistance
1.2 Antibacterial (Drug) Resistance Segment by Type
1.2.1 Global Antibacterial (Drug) Resistance Market Value Comparison by Type (2024-2030)
1.2.2 Telavancin (Vibativ)
1.2.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
1.2.4 Fidaxomicin (Dificid / Dificlir)
1.2.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
1.2.6 Dalbavancin (Dalvance/ Xydalba)
1.2.7 Tedizolid Phosphate (Sivextro)
1.2.8 Oritavancin (Orbactiv/ Nuvocid)
1.2.9 Ceftolozane-Tazobactam (Zerbaxa)
1.2.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
1.2.11 PHASE III DRUGS
1.3 Antibacterial (Drug) Resistance Segment by Indication
1.3.1 Global Antibacterial (Drug) Resistance Market Value by Indication: (2024-2030)
1.3.2 Complicated Urinary Tract Infection (CUTI)
1.3.3 Complicated Intra-Abdominal Infections (CIAI)
1.3.4 Blood Stream Infections (BSI)
1.3.5 Clostridium Difficile Infections (CDI)
1.3.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
1.3.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
1.3.8 Community Acquired Bacterial Pneumonia (CABP)
1.4 Global Antibacterial (Drug) Resistance Market Size Estimates and Forecasts
1.4.1 Global Antibacterial (Drug) Resistance Revenue 2019-2030
1.4.2 Global Antibacterial (Drug) Resistance Sales 2019-2030
1.4.3 Global Antibacterial (Drug) Resistance Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antibacterial (Drug) Resistance Market Competition by Manufacturers
2.1 Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antibacterial (Drug) Resistance Average Price by Manufacturers (2019-2024)
2.4 Global Antibacterial (Drug) Resistance Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antibacterial (Drug) Resistance, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antibacterial (Drug) Resistance, Product Type & Application
2.7 Antibacterial (Drug) Resistance Market Competitive Situation and Trends
2.7.1 Antibacterial (Drug) Resistance Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antibacterial (Drug) Resistance Players Market Share by Revenue
2.7.3 Global Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antibacterial (Drug) Resistance Retrospective Market Scenario by Region
3.1 Global Antibacterial (Drug) Resistance Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antibacterial (Drug) Resistance Global Antibacterial (Drug) Resistance Sales by Region: 2019-2030
3.2.1 Global Antibacterial (Drug) Resistance Sales by Region: 2019-2024
3.2.2 Global Antibacterial (Drug) Resistance Sales by Region: 2025-2030
3.3 Global Antibacterial (Drug) Resistance Global Antibacterial (Drug) Resistance Revenue by Region: 2019-2030
3.3.1 Global Antibacterial (Drug) Resistance Revenue by Region: 2019-2024
3.3.2 Global Antibacterial (Drug) Resistance Revenue by Region: 2025-2030
3.4 North America Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.4.1 North America Antibacterial (Drug) Resistance Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antibacterial (Drug) Resistance Sales by Country (2019-2030)
3.4.3 North America Antibacterial (Drug) Resistance Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.5.1 Europe Antibacterial (Drug) Resistance Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antibacterial (Drug) Resistance Sales by Country (2019-2030)
3.5.3 Europe Antibacterial (Drug) Resistance Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.6.1 Asia Pacific Antibacterial (Drug) Resistance Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antibacterial (Drug) Resistance Sales by Country (2019-2030)
3.6.3 Asia Pacific Antibacterial (Drug) Resistance Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.7.1 Latin America Antibacterial (Drug) Resistance Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antibacterial (Drug) Resistance Sales by Country (2019-2030)
3.7.3 Latin America Antibacterial (Drug) Resistance Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.8.1 Middle East and Africa Antibacterial (Drug) Resistance Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antibacterial (Drug) Resistance Sales by Type (2019-2030)
4.1.1 Global Antibacterial (Drug) Resistance Sales by Type (2019-2024)
4.1.2 Global Antibacterial (Drug) Resistance Sales by Type (2025-2030)
4.1.3 Global Antibacterial (Drug) Resistance Sales Market Share by Type (2019-2030)
4.2 Global Antibacterial (Drug) Resistance Revenue by Type (2019-2030)
4.2.1 Global Antibacterial (Drug) Resistance Revenue by Type (2019-2024)
4.2.2 Global Antibacterial (Drug) Resistance Revenue by Type (2025-2030)
4.2.3 Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2019-2030)
4.3 Global Antibacterial (Drug) Resistance Price by Type (2019-2030)
5 Segment by Indication
5.1 Global Antibacterial (Drug) Resistance Sales by Indication (2019-2030)
5.1.1 Global Antibacterial (Drug) Resistance Sales by Indication (2019-2024)
5.1.2 Global Antibacterial (Drug) Resistance Sales by Indication (2025-2030)
5.1.3 Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2019-2030)
5.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2019-2030)
5.2.1 Global Antibacterial (Drug) Resistance Revenue by Indication (2019-2024)
5.2.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2025-2030)
5.2.3 Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2019-2030)
5.3 Global Antibacterial (Drug) Resistance Price by Indication (2019-2030)
6 Key Companies Profiled
6.1 Melinta Therapeutics
6.1.1 Melinta Therapeutics Corporation Information
6.1.2 Melinta Therapeutics Description and Business Overview
6.1.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio
6.1.5 Melinta Therapeutics Recent Developments/Updates
6.2 Allergan
6.2.1 Allergan Corporation Information
6.2.2 Allergan Description and Business Overview
6.2.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Allergan Antibacterial (Drug) Resistance Product Portfolio
6.2.5 Allergan Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Antibacterial (Drug) Resistance Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Abbott Laboratories
6.4.1 Abbott Laboratories Corporation Information
6.4.2 Abbott Laboratories Description and Business Overview
6.4.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio
6.4.5 Abbott Laboratories Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Antibacterial (Drug) Resistance Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GSK Antibacterial (Drug) Resistance Product Portfolio
6.6.5 GSK Recent Developments/Updates
6.7 PENDOPHARM
6.6.1 PENDOPHARM Corporation Information
6.6.2 PENDOPHARM Description and Business Overview
6.6.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.4.4 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio
6.7.5 PENDOPHARM Recent Developments/Updates
6.8 Absynth Biologics
6.8.1 Absynth Biologics Corporation Information
6.8.2 Absynth Biologics Description and Business Overview
6.8.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio
6.8.5 Absynth Biologics Recent Developments/Updates
6.9 Achaogen
6.9.1 Achaogen Corporation Information
6.9.2 Achaogen Description and Business Overview
6.9.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Achaogen Antibacterial (Drug) Resistance Product Portfolio
6.9.5 Achaogen Recent Developments/Updates
6.10 Acino Holdings
6.10.1 Acino Holdings Corporation Information
6.10.2 Acino Holdings Description and Business Overview
6.10.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Acino Holdings Antibacterial (Drug) Resistance Product Portfolio
6.10.5 Acino Holdings Recent Developments/Updates
6.11 Aventis Pharma
6.11.1 Aventis Pharma Corporation Information
6.11.2 Aventis Pharma Antibacterial (Drug) Resistance Description and Business Overview
6.11.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio
6.11.5 Aventis Pharma Recent Developments/Updates
6.12 Austell Laboratories
6.12.1 Austell Laboratories Corporation Information
6.12.2 Austell Laboratories Antibacterial (Drug) Resistance Description and Business Overview
6.12.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio
6.12.5 Austell Laboratories Recent Developments/Updates
6.13 Assembly Biosciences
6.13.1 Assembly Biosciences Corporation Information
6.13.2 Assembly Biosciences Antibacterial (Drug) Resistance Description and Business Overview
6.13.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio
6.13.5 Assembly Biosciences Recent Developments/Updates
6.14 Arpida
6.14.1 Arpida Corporation Information
6.14.2 Arpida Antibacterial (Drug) Resistance Description and Business Overview
6.14.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Arpida Antibacterial (Drug) Resistance Product Portfolio
6.14.5 Arpida Recent Developments/Updates
6.15 Demuris
6.15.1 Demuris Corporation Information
6.15.2 Demuris Antibacterial (Drug) Resistance Description and Business Overview
6.15.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Demuris Antibacterial (Drug) Resistance Product Portfolio
6.15.5 Demuris Recent Developments/Updates
6.16 Evolva Holding
6.16.1 Evolva Holding Corporation Information
6.16.2 Evolva Holding Antibacterial (Drug) Resistance Description and Business Overview
6.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Portfolio
6.16.5 Evolva Holding Recent Developments/Updates
6.17 ContraFect
6.17.1 ContraFect Corporation Information
6.17.2 ContraFect Antibacterial (Drug) Resistance Description and Business Overview
6.17.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.17.4 ContraFect Antibacterial (Drug) Resistance Product Portfolio
6.17.5 ContraFect Recent Developments/Updates
6.18 Cerexa
6.18.1 Cerexa Corporation Information
6.18.2 Cerexa Antibacterial (Drug) Resistance Description and Business Overview
6.18.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Cerexa Antibacterial (Drug) Resistance Product Portfolio
6.18.5 Cerexa Recent Developments/Updates
6.19 InterMune
6.19.1 InterMune Corporation Information
6.19.2 InterMune Antibacterial (Drug) Resistance Description and Business Overview
6.19.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.19.4 InterMune Antibacterial (Drug) Resistance Product Portfolio
6.19.5 InterMune Recent Developments/Updates
6.20 Isis Pharmaceuticals
6.20.1 Isis Pharmaceuticals Corporation Information
6.20.2 Isis Pharmaceuticals Antibacterial (Drug) Resistance Description and Business Overview
6.20.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
6.20.5 Isis Pharmaceuticals Recent Developments/Updates
6.21 Lyndra
6.21.1 Lyndra Corporation Information
6.21.2 Lyndra Antibacterial (Drug) Resistance Description and Business Overview
6.21.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Lyndra Antibacterial (Drug) Resistance Product Portfolio
6.21.5 Lyndra Recent Developments/Updates
6.22 Microbecide
6.22.1 Microbecide Corporation Information
6.22.2 Microbecide Antibacterial (Drug) Resistance Description and Business Overview
6.22.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Microbecide Antibacterial (Drug) Resistance Product Portfolio
6.22.5 Microbecide Recent Developments/Updates
6.23 Morphochem
6.23.1 Morphochem Corporation Information
6.23.2 Morphochem Antibacterial (Drug) Resistance Description and Business Overview
6.23.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Morphochem Antibacterial (Drug) Resistance Product Portfolio
6.23.5 Morphochem Recent Developments/Updates
6.24 Nabriva Therapeutics
6.24.1 Nabriva Therapeutics Corporation Information
6.24.2 Nabriva Therapeutics Antibacterial (Drug) Resistance Description and Business Overview
6.24.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio
6.24.5 Nabriva Therapeutics Recent Developments/Updates
6.25 NanoSafe Coatings
6.25.1 NanoSafe Coatings Corporation Information
6.25.2 NanoSafe Coatings Antibacterial (Drug) Resistance Description and Business Overview
6.25.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.25.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio
6.25.5 NanoSafe Coatings Recent Developments/Updates
6.26 Novexel
6.26.1 Novexel Corporation Information
6.26.2 Novexel Antibacterial (Drug) Resistance Description and Business Overview
6.26.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Novexel Antibacterial (Drug) Resistance Product Portfolio
6.26.5 Novexel Recent Developments/Updates
6.27 Osel
6.27.1 Osel Corporation Information
6.27.2 Osel Antibacterial (Drug) Resistance Description and Business Overview
6.27.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.27.4 Osel Antibacterial (Drug) Resistance Product Portfolio
6.27.5 Osel Recent Developments/Updates
6.28 VenatoRx Pharmaceuticals
6.28.1 VenatoRx Pharmaceuticals Corporation Information
6.28.2 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Description and Business Overview
6.28.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.28.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
6.28.5 VenatoRx Pharmaceuticals Recent Developments/Updates
6.29 AAIPharma Services
6.29.1 AAIPharma Services Corporation Information
6.29.2 AAIPharma Services Antibacterial (Drug) Resistance Description and Business Overview
6.29.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.29.4 AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio
6.29.5 AAIPharma Services Recent Developments/Updates
6.30 ANTABIO
6.30.1 ANTABIO Corporation Information
6.30.2 ANTABIO Antibacterial (Drug) Resistance Description and Business Overview
6.30.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
6.30.4 ANTABIO Antibacterial (Drug) Resistance Product Portfolio
6.30.5 ANTABIO Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antibacterial (Drug) Resistance Industry Chain Analysis
7.2 Antibacterial (Drug) Resistance Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antibacterial (Drug) Resistance Production Mode & Process
7.4 Antibacterial (Drug) Resistance Sales and Marketing
7.4.1 Antibacterial (Drug) Resistance Sales Channels
7.4.2 Antibacterial (Drug) Resistance Distributors
7.5 Antibacterial (Drug) Resistance Customers
8 Antibacterial (Drug) Resistance Market Dynamics
8.1 Antibacterial (Drug) Resistance Industry Trends
8.2 Antibacterial (Drug) Resistance Market Drivers
8.3 Antibacterial (Drug) Resistance Market Challenges
8.4 Antibacterial (Drug) Resistance Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Antibacterial (Drug) Resistance Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Antibacterial (Drug) Resistance Market Value Comparison by Indication (2024-2030) & (US$ Million)
Table 3. Global Antibacterial (Drug) Resistance Market Competitive Situation by Manufacturers in 2023
Table 4. Global Antibacterial (Drug) Resistance Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Antibacterial (Drug) Resistance Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Antibacterial (Drug) Resistance, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Antibacterial (Drug) Resistance, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Antibacterial (Drug) Resistance, Product Type & Application
Table 12. Global Key Manufacturers of Antibacterial (Drug) Resistance, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibacterial (Drug) Resistance as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antibacterial (Drug) Resistance Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Antibacterial (Drug) Resistance Sales by Region (2019-2024) & (K Units)
Table 18. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2019-2024)
Table 19. Global Antibacterial (Drug) Resistance Sales by Region (2025-2030) & (K Units)
Table 20. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2025-2030)
Table 21. Global Antibacterial (Drug) Resistance Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2019-2024)
Table 23. Global Antibacterial (Drug) Resistance Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2025-2030)
Table 25. North America Antibacterial (Drug) Resistance Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Antibacterial (Drug) Resistance Sales by Country (2019-2024) & (K Units)
Table 27. North America Antibacterial (Drug) Resistance Sales by Country (2025-2030) & (K Units)
Table 28. North America Antibacterial (Drug) Resistance Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Antibacterial (Drug) Resistance Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Antibacterial (Drug) Resistance Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Antibacterial (Drug) Resistance Sales by Country (2019-2024) & (K Units)
Table 32. Europe Antibacterial (Drug) Resistance Sales by Country (2025-2030) & (K Units)
Table 33. Europe Antibacterial (Drug) Resistance Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Antibacterial (Drug) Resistance Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Antibacterial (Drug) Resistance Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Antibacterial (Drug) Resistance Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Antibacterial (Drug) Resistance Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Antibacterial (Drug) Resistance Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Antibacterial (Drug) Resistance Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Antibacterial (Drug) Resistance Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Antibacterial (Drug) Resistance Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Antibacterial (Drug) Resistance Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Antibacterial (Drug) Resistance Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Antibacterial (Drug) Resistance Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Antibacterial (Drug) Resistance Sales (K Units) by Type (2019-2024)
Table 51. Global Antibacterial (Drug) Resistance Sales (K Units) by Type (2025-2030)
Table 52. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2019-2024)
Table 53. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2025-2030)
Table 54. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2019-2024)
Table 57. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2025-2030)
Table 58. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2019-2024)
Table 59. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2025-2030)
Table 60. Global Antibacterial (Drug) Resistance Sales (K Units) by Indication (2019-2024)
Table 61. Global Antibacterial (Drug) Resistance Sales (K Units) by Indication (2025-2030)
Table 62. Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2019-2024)
Table 63. Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2025-2030)
Table 64. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Indication (2019-2024)
Table 65. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Indication (2025-2030)
Table 66. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2019-2024)
Table 67. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2025-2030)
Table 68. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2019-2024)
Table 69. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2025-2030)
Table 70. Melinta Therapeutics Corporation Information
Table 71. Melinta Therapeutics Description and Business Overview
Table 72. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Melinta Therapeutics Antibacterial (Drug) Resistance Product
Table 74. Melinta Therapeutics Recent Developments/Updates
Table 75. Allergan Corporation Information
Table 76. Allergan Description and Business Overview
Table 77. Allergan Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Allergan Antibacterial (Drug) Resistance Product
Table 79. Allergan Recent Developments/Updates
Table 80. Merck Corporation Information
Table 81. Merck Description and Business Overview
Table 82. Merck Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Merck Antibacterial (Drug) Resistance Product
Table 84. Merck Recent Developments/Updates
Table 85. Abbott Laboratories Corporation Information
Table 86. Abbott Laboratories Description and Business Overview
Table 87. Abbott Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Abbott Laboratories Antibacterial (Drug) Resistance Product
Table 89. Abbott Laboratories Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Pfizer Antibacterial (Drug) Resistance Product
Table 94. Pfizer Recent Developments/Updates
Table 95. GSK Corporation Information
Table 96. GSK Description and Business Overview
Table 97. GSK Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. GSK Antibacterial (Drug) Resistance Product
Table 99. GSK Recent Developments/Updates
Table 100. PENDOPHARM Corporation Information
Table 101. PENDOPHARM Description and Business Overview
Table 102. PENDOPHARM Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. PENDOPHARM Antibacterial (Drug) Resistance Product
Table 104. PENDOPHARM Recent Developments/Updates
Table 105. Absynth Biologics Corporation Information
Table 106. Absynth Biologics Description and Business Overview
Table 107. Absynth Biologics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Absynth Biologics Antibacterial (Drug) Resistance Product
Table 109. Absynth Biologics Recent Developments/Updates
Table 110. Achaogen Corporation Information
Table 111. Achaogen Description and Business Overview
Table 112. Achaogen Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Achaogen Antibacterial (Drug) Resistance Product
Table 114. Achaogen Recent Developments/Updates
Table 115. Acino Holdings Corporation Information
Table 116. Acino Holdings Description and Business Overview
Table 117. Acino Holdings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Acino Holdings Antibacterial (Drug) Resistance Product
Table 119. Acino Holdings Recent Developments/Updates
Table 120. Aventis Pharma Corporation Information
Table 121. Aventis Pharma Description and Business Overview
Table 122. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. Aventis Pharma Antibacterial (Drug) Resistance Product
Table 124. Aventis Pharma Recent Developments/Updates
Table 125. Austell Laboratories Corporation Information
Table 126. Austell Laboratories Description and Business Overview
Table 127. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. Austell Laboratories Antibacterial (Drug) Resistance Product
Table 129. Austell Laboratories Recent Developments/Updates
Table 130. Assembly Biosciences Corporation Information
Table 131. Assembly Biosciences Description and Business Overview
Table 132. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. Assembly Biosciences Antibacterial (Drug) Resistance Product
Table 134. Assembly Biosciences Recent Developments/Updates
Table 135. Arpida Corporation Information
Table 136. Arpida Description and Business Overview
Table 137. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. Arpida Antibacterial (Drug) Resistance Product
Table 139. Arpida Recent Developments/Updates
Table 140. Demuris Corporation Information
Table 141. Demuris Description and Business Overview
Table 142. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 143. Demuris Antibacterial (Drug) Resistance Product
Table 144. Demuris Recent Developments/Updates
Table 145. Evolva Holding Corporation Information
Table 146. Evolva Holding Description and Business Overview
Table 147. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 148. Evolva Holding Antibacterial (Drug) Resistance Product
Table 149. Evolva Holding Recent Developments/Updates
Table 150. ContraFect Corporation Information
Table 151. ContraFect Description and Business Overview
Table 152. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 153. ContraFect Antibacterial (Drug) Resistance Product
Table 154. ContraFect Recent Developments/Updates
Table 155. Cerexa Corporation Information
Table 156. Cerexa Description and Business Overview
Table 157. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 158. Cerexa Antibacterial (Drug) Resistance Product
Table 159. Cerexa Recent Developments/Updates
Table 160. InterMune Corporation Information
Table 161. InterMune Description and Business Overview
Table 162. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 163. InterMune Antibacterial (Drug) Resistance Product
Table 164. InterMune Recent Developments/Updates
Table 165. Isis Pharmaceuticals Corporation Information
Table 166. Isis Pharmaceuticals Description and Business Overview
Table 167. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 168. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product
Table 169. Isis Pharmaceuticals Recent Developments/Updates
Table 170. Lyndra Corporation Information
Table 171. Lyndra Description and Business Overview
Table 172. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 173. Lyndra Antibacterial (Drug) Resistance Product
Table 174. Lyndra Recent Developments/Updates
Table 175. Microbecide Corporation Information
Table 176. Microbecide Description and Business Overview
Table 177. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 178. Microbecide Antibacterial (Drug) Resistance Product
Table 179. Microbecide Recent Developments/Updates
Table 180. Morphochem Corporation Information
Table 181. Morphochem Description and Business Overview
Table 182. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 183. Morphochem Antibacterial (Drug) Resistance Product
Table 184. Morphochem Recent Developments/Updates
Table 185. Nabriva Therapeutics Corporation Information
Table 186. Nabriva Therapeutics Description and Business Overview
Table 187. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 188. Nabriva Therapeutics Antibacterial (Drug) Resistance Product
Table 189. Nabriva Therapeutics Recent Developments/Updates
Table 190. NanoSafe Coatings Corporation Information
Table 191. NanoSafe Coatings Description and Business Overview
Table 192. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 193. NanoSafe Coatings Antibacterial (Drug) Resistance Product
Table 194. NanoSafe Coatings Recent Developments/Updates
Table 195. Novexel Corporation Information
Table 196. Novexel Description and Business Overview
Table 197. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 198. Novexel Antibacterial (Drug) Resistance Product
Table 199. Novexel Recent Developments/Updates
Table 200. Osel Corporation Information
Table 201. Osel Description and Business Overview
Table 202. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 203. Osel Antibacterial (Drug) Resistance Product
Table 204. Osel Recent Developments/Updates
Table 205. VenatoRx Pharmaceuticals Corporation Information
Table 206. VenatoRx Pharmaceuticals Description and Business Overview
Table 207. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 208. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product
Table 209. VenatoRx Pharmaceuticals Recent Developments/Updates
Table 210. AAIPharma Services Corporation Information
Table 211. AAIPharma Services Description and Business Overview
Table 212. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 213. AAIPharma Services Antibacterial (Drug) Resistance Product
Table 214. AAIPharma Services Recent Developments/Updates
Table 215. ANTABIO Corporation Information
Table 216. ANTABIO Description and Business Overview
Table 217. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 218. ANTABIO Antibacterial (Drug) Resistance Product
Table 219. ANTABIO Recent Developments/Updates
Table 220. Key Raw Materials Lists
Table 221. Raw Materials Key Suppliers Lists
Table 222. Antibacterial (Drug) Resistance Distributors List
Table 223. Antibacterial (Drug) Resistance Customers List
Table 224. Antibacterial (Drug) Resistance Market Trends
Table 225. Antibacterial (Drug) Resistance Market Drivers
Table 226. Antibacterial (Drug) Resistance Market Challenges
Table 227. Antibacterial (Drug) Resistance Market Restraints
Table 228. Research Programs/Design for This Report
Table 229. Key Data Information from Secondary Sources
Table 230. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Antibacterial (Drug) Resistance
Figure 2. Global Antibacterial (Drug) Resistance Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Antibacterial (Drug) Resistance Market Share by Type in 2023 & 2030
Figure 4. Telavancin (Vibativ) Product Picture
Figure 5. Ceftaroline Fosamil (Teflaro/ Zinforo) Product Picture
Figure 6. Fidaxomicin (Dificid / Dificlir) Product Picture
Figure 7. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Product Picture
Figure 8. Dalbavancin (Dalvance/ Xydalba) Product Picture
Figure 9. Tedizolid Phosphate (Sivextro) Product Picture
Figure 10. Oritavancin (Orbactiv/ Nuvocid) Product Picture
Figure 11. Ceftolozane-Tazobactam (Zerbaxa) Product Picture
Figure 12. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Product Picture
Figure 13. PHASE III DRUGS Product Picture
Figure 14. Global Antibacterial (Drug) Resistance Market Value Comparison by Indication (2024-2030) & (US$ Million)
Figure 15. Global Antibacterial (Drug) Resistance Market Share by Indication in 2023 & 2030
Figure 16. Complicated Urinary Tract Infection (CUTI)
Figure 17. Complicated Intra-Abdominal Infections (CIAI)
Figure 18. Blood Stream Infections (BSI)
Figure 19. Clostridium Difficile Infections (CDI)
Figure 20. Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Figure 21. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Figure 22. Community Acquired Bacterial Pneumonia (CABP)
Figure 23. Global Antibacterial (Drug) Resistance Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 24. Global Antibacterial (Drug) Resistance Market Size (2019-2030) & (US$ Million)
Figure 25. Global Antibacterial (Drug) Resistance Sales (2019-2030) & (K Units)
Figure 26. Global Antibacterial (Drug) Resistance Average Price (USD/Unit) & (2019-2030)
Figure 27. Antibacterial (Drug) Resistance Report Years Considered
Figure 28. Antibacterial (Drug) Resistance Sales Share by Manufacturers in 2023
Figure 29. Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers in 2023
Figure 30. The Global 5 and 10 Largest Antibacterial (Drug) Resistance Players: Market Share by Revenue in 2023
Figure 31. Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 32. Global Antibacterial (Drug) Resistance Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 33. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2019-2030)
Figure 34. North America Antibacterial (Drug) Resistance Revenue Market Share by Country (2019-2030)
Figure 35. U.S. Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Canada Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2019-2030)
Figure 38. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country (2019-2030)
Figure 39. Germany Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. France Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. U.K. Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Italy Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Russia Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region (2019-2030)
Figure 45. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region (2019-2030)
Figure 46. China Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Japan Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. South Korea Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. India Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Australia Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. China Taiwan Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Indonesia Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Thailand Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Malaysia Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country (2019-2030)
Figure 56. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country (2019-2030)
Figure 57. Mexico Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Brazil Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 59. Argentina Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 60. Middle East & Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2019-2030)
Figure 61. Middle East & Africa Antibacterial (Drug) Resistance Revenue Market Share by Country (2019-2030)
Figure 62. Turkey Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 63. Saudi Arabia Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 64. UAE Antibacterial (Drug) Resistance Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 65. Global Sales Market Share of Antibacterial (Drug) Resistance by Type (2019-2030)
Figure 66. Global Revenue Market Share of Antibacterial (Drug) Resistance by Type (2019-2030)
Figure 67. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2019-2030)
Figure 68. Global Sales Market Share of Antibacterial (Drug) Resistance by Indication (2019-2030)
Figure 69. Global Revenue Market Share of Antibacterial (Drug) Resistance by Indication (2019-2030)
Figure 70. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2019-2030)
Figure 71. Antibacterial (Drug) Resistance Value Chain
Figure 72. Antibacterial (Drug) Resistance Production Process
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Distributors Profiles
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
